Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,910,307
  • Shares Outstanding, K 237,998
  • Annual Sales, $ 426,450 K
  • Annual Income, $ 197,670 K
  • EBIT $ 167 M
  • EBITDA $ 176 M
  • 60-Month Beta 0.49
  • Price/Sales 8.28
  • Price/Cash Flow 29.45
  • Price/Book 8.81

Options Overview Details

View History
  • Implied Volatility 70.57% (-18.23%)
  • Historical Volatility 38.83%
  • IV Percentile 76%
  • IV Rank 48.58%
  • IV High 103.47% on 02/12/25
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 12) 1.17 (7.14%)
  • Put/Call Vol Ratio 6.32
  • Today's Volume 1,501
  • Volume Avg (30-Day) 2,154
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 39,432
  • Open Int (30-Day) 50,676
  • Expected Range 15.26 to 17.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.14
  • Growth Rate Est. (year over year) +713,471.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.79 +4.05%
on 02/05/26
18.95 -13.30%
on 01/07/26
-1.91 (-10.41%)
since 01/06/26
3-Month
13.76 +19.40%
on 11/07/25
20.46 -19.69%
on 12/12/25
+2.40 (+17.11%)
since 11/06/25
52-Week
13.50 +21.70%
on 03/04/25
25.67 -36.00%
on 04/28/25
-0.49 (-2.90%)
since 02/06/25

Most Recent Stories

More News
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update

FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA (1) and Adjusted Net Income (2) Guidance...

ADMA : 16.43 (+3.07%)
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company...

ADMA : 16.43 (+3.07%)
Adma Biologics: Q3 Earnings Snapshot

Adma Biologics: Q3 Earnings Snapshot

ADMA : 16.43 (+3.07%)
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update

3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase  3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase...

ADMA : 16.43 (+3.07%)
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...

ADMA : 16.43 (+3.07%)
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum

ADMA Biologics (ADMA) reported better-than-expected results for the second quarter. Adjusted earnings per share of 15 cents beat the Zacks Consensus Estimate by a penny.Revenues of $122 million (up 14%...

IMCR : 31.98 (+3.43%)
CRMD : 7.69 (+4.63%)
ADMA : 16.43 (+3.07%)
Adma Biologics: Q2 Earnings Snapshot

Adma Biologics: Q2 Earnings Snapshot

ADMA : 16.43 (+3.07%)
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update

2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025...

ADMA : 16.43 (+3.07%)
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025

RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...

ADMA : 16.43 (+3.07%)
Implied Volatility Surging for ADMA Biologics Stock Options

Investors in ADMA Biologics, Inc. ADMA need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 16, 2026 $5.00 Call had some of the highest implied...

ADMA : 16.43 (+3.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 17.17
2nd Resistance Point 16.88
1st Resistance Point 16.66
Last Price 16.43
1st Support Level 16.15
2nd Support Level 15.86
3rd Support Level 15.64

See More

52-Week High 25.67
Fibonacci 61.8% 21.02
Fibonacci 50% 19.58
Fibonacci 38.2% 18.15
Last Price 16.43
52-Week Low 13.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar